ATE499112T1 - Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten - Google Patents
Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheitenInfo
- Publication number
- ATE499112T1 ATE499112T1 AT06824878T AT06824878T ATE499112T1 AT E499112 T1 ATE499112 T1 AT E499112T1 AT 06824878 T AT06824878 T AT 06824878T AT 06824878 T AT06824878 T AT 06824878T AT E499112 T1 ATE499112 T1 AT E499112T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine
- infectious diseases
- immunomodulatory compounds
- against infectious
- therapy against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71282305P | 2005-09-01 | 2005-09-01 | |
PCT/US2006/034271 WO2007028047A2 (en) | 2005-09-01 | 2006-08-31 | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE499112T1 true ATE499112T1 (de) | 2011-03-15 |
Family
ID=37806889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06824878T ATE499112T1 (de) | 2005-09-01 | 2006-08-31 | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten |
Country Status (14)
Country | Link |
---|---|
US (2) | US8715677B2 (de) |
EP (2) | EP2301535B1 (de) |
JP (2) | JP2009507030A (de) |
AT (1) | ATE499112T1 (de) |
CA (1) | CA2621136C (de) |
CY (1) | CY1112325T1 (de) |
DE (1) | DE602006020300D1 (de) |
DK (1) | DK1928492T3 (de) |
ES (2) | ES2359162T3 (de) |
HR (1) | HRP20110348T1 (de) |
PL (1) | PL1928492T3 (de) |
RS (1) | RS51840B (de) |
SI (1) | SI1928492T1 (de) |
WO (1) | WO2007028047A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068210A1 (en) * | 2007-07-09 | 2009-03-12 | Munshi Nikhil C | Immunotherapy for hematological malignancies |
US9200253B1 (en) * | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
US8012466B2 (en) | 2008-01-31 | 2011-09-06 | University Of Iowa Research Foundation | Immunogenic compositions for activating γδ T cells |
WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
MX2011004470A (es) | 2008-10-29 | 2011-05-31 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
TR201905423T4 (tr) | 2009-05-19 | 2019-05-21 | Celgene Corp | 4-amino-2-(2,6-dioksopiperidin-3-il)izindolin-1,3-dion'un formülasyonları |
WO2011079091A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
EP3578205A1 (de) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
EP2663549B1 (de) | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
EP2691101A2 (de) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
MX356105B (es) | 2011-09-14 | 2018-05-14 | Celgene Corp | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
PL2797581T3 (pl) | 2011-12-27 | 2020-10-05 | Amgen (Europe) GmbH | Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US20150174235A1 (en) | 2012-06-06 | 2015-06-25 | Bionor Immuno As | Vaccine |
TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
EP2764866A1 (de) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Hemmer der nedd8-aktivierenden Enzyme |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AU2014248263A1 (en) | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
EP2801364A1 (de) * | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonellenstamm zur Verwendung bei der Behandlung und/oder Vorbeugung von Krebs |
EP2815749A1 (de) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
EP3052106A4 (de) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynukleotide zur codierung immunmodulierender polypeptide |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
CA2951616A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
US20180140694A1 (en) | 2015-05-04 | 2018-05-24 | Bionor Immuno As | Dosage regimen for hiv vaccine |
TWI727211B (zh) * | 2018-09-27 | 2021-05-11 | 大江生醫股份有限公司 | 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
JP2984366B2 (ja) * | 1989-04-05 | 1999-11-29 | バイオミラ、インコーポレーテッド | 免疫抑制ムチンを生成する腺がんの能動的特異免疫療法 |
WO1993013772A1 (en) * | 1992-01-21 | 1993-07-22 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
ES2529190T3 (es) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
BR9908811A (pt) | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
ATE306469T1 (de) | 1999-03-18 | 2005-10-15 | Celgene Corp | Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine |
AU2593701A (en) * | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
AU2003224989B2 (en) * | 2002-04-19 | 2008-12-04 | Endocyte, Inc. | Adjuvant enhanced immunotherapy |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
EP2915533B1 (de) * | 2002-05-17 | 2017-09-13 | Celgene Corporation | Pharmazeutische Zusammensetzungen zur Behandlung von Krebs |
CA2501940A1 (en) * | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
US20060240024A1 (en) * | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
EP1660126A1 (de) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonisten oder antagonisten des glucocorticoid-induzierten tumor-nekosefaktor-rezeptors (gitr) oder seiner liganden zur behandlung von immunstörungen, infektionen und krebs |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2006
- 2006-08-31 RS RS20110194A patent/RS51840B/en unknown
- 2006-08-31 EP EP11151126.7A patent/EP2301535B1/de active Active
- 2006-08-31 ES ES06824878T patent/ES2359162T3/es active Active
- 2006-08-31 DE DE602006020300T patent/DE602006020300D1/de active Active
- 2006-08-31 AT AT06824878T patent/ATE499112T1/de active
- 2006-08-31 ES ES11151126.7T patent/ES2485316T3/es active Active
- 2006-08-31 DK DK06824878.0T patent/DK1928492T3/da active
- 2006-08-31 EP EP06824878A patent/EP1928492B1/de active Active
- 2006-08-31 PL PL06824878T patent/PL1928492T3/pl unknown
- 2006-08-31 US US11/514,447 patent/US8715677B2/en not_active Expired - Fee Related
- 2006-08-31 CA CA2621136A patent/CA2621136C/en not_active Expired - Fee Related
- 2006-08-31 SI SI200631013T patent/SI1928492T1/sl unknown
- 2006-08-31 JP JP2008529318A patent/JP2009507030A/ja not_active Withdrawn
- 2006-08-31 WO PCT/US2006/034271 patent/WO2007028047A2/en active Application Filing
-
2011
- 2011-04-13 CY CY20111100376T patent/CY1112325T1/el unknown
- 2011-05-10 HR HR20110348T patent/HRP20110348T1/hr unknown
-
2012
- 2012-04-02 US US13/437,739 patent/US20120190110A1/en not_active Abandoned
-
2013
- 2013-07-03 JP JP2013140191A patent/JP5796040B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SI1928492T1 (sl) | 2011-09-30 |
PL1928492T3 (pl) | 2011-09-30 |
CA2621136C (en) | 2014-10-14 |
EP2301535B1 (de) | 2014-05-28 |
JP5796040B2 (ja) | 2015-10-21 |
CA2621136A1 (en) | 2007-03-08 |
DK1928492T3 (da) | 2011-06-06 |
RS51840B (en) | 2012-02-29 |
WO2007028047A2 (en) | 2007-03-08 |
US20070048327A1 (en) | 2007-03-01 |
ES2359162T3 (es) | 2011-05-19 |
JP2009507030A (ja) | 2009-02-19 |
WO2007028047A3 (en) | 2007-06-14 |
ES2485316T3 (es) | 2014-08-13 |
US20120190110A1 (en) | 2012-07-26 |
EP2301535A1 (de) | 2011-03-30 |
HRP20110348T1 (hr) | 2011-07-31 |
EP1928492A2 (de) | 2008-06-11 |
EP1928492B1 (de) | 2011-02-23 |
US8715677B2 (en) | 2014-05-06 |
DE602006020300D1 (de) | 2011-04-07 |
JP2013241424A (ja) | 2013-12-05 |
CY1112325T1 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE499112T1 (de) | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten | |
EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
WO2007079190A3 (en) | Device and method for enhancing immune response by electrical stimulation | |
FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
ATE473760T1 (de) | Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor | |
DE602004020189D1 (de) | Adjuvante influenza-vakzine | |
NO20051345L (no) | Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer | |
WO2008083239A3 (en) | Compositions and methods for stimulating an immune response | |
CY1109914T1 (el) | Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
SE0501903L (sv) | Borföreningar användbara vid BNCT | |
ATE530569T1 (de) | Assays zum nachweis von tuberkulose- antigenen, und impfstoffe | |
ATE460943T1 (de) | Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren | |
SE0302312D0 (sv) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
DE602005010844D1 (de) | Pharmazeutische zusammensetzungen mit interferon-tau | |
EA200700017A1 (ru) | Способ усиления иммунного ответа на вакцину | |
ATE515270T1 (de) | Phep, eine aminosäurepermease von staphylococcus aureus | |
ATE544856T1 (de) | Peptid- und nukleotidsequenzen von anisakis spp. und ihre verwendung | |
RU2004130267A (ru) | Способ вакцинации детей против краснухи на крайнем севере | |
WO2009008888A8 (en) | African swine virus polypeptides as vaccines and its therapeutic use thereof | |
RU2004103757A (ru) | Способ лечения миксоматоза кроликов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1928492 Country of ref document: EP |